Jordi Clarimon
Neurological Disorders & Biofluid Specialist Lundbeck
Jordi is a biomarker and translational science leader with more than 20 years of experience in neurological disorders and over 250 peer-reviewed publications. After transitioning from academia to the pharmaceutical industry in 2020, he has led biomarker strategies across neuroimmunology and neurodegeneration programs, spanning preclinical research through Phase III clinical development. Working within global cross-functional teams, Jordi collaborates across Therapeutic Areas, Data Science, Bioanalysis, PK Modeling, Research, and Bioinformatics to advance innovative therapies. His expertise lies in translating biomarker insights into actionable evidence that supports decision-making, reduces development risk, and improves the likelihood of clinical success.
Seminars
- Explore how α-synuclein seed amplification assays are enabling earlier, pathology-driven patient identification
- Examine the opportunities and challenges of applying emerging biomarker technologies in rare neurodegenerative diseases, where limited patient populations require innovative validation approaches
- Discuss how lessons learned from Parkinson’s disease biomarker development can accelerate clinical trial design, patient stratification, and therapeutic development in MSA and related disorders
